Compositions comprising bacterial strains
First Claim
Patent Images
1. A pharmaceutical composition that reduces inflammation associated with Th17 differentiation in a subject in need thereof, that comprises a therapeutically effective amount of a single bacteria strain of the species Erysipelatoclostridium ramosum;
- anda pharmaceutically acceptable excipient, diluent, or carrier;
wherein the therapeutically effective amount comprises from about 1×
103 to about 1×
1011 CFU of the bacteria strain;
wherein the bacterial strain is lyophilized; and
wherein the bacteria strain comprises a polynucleotide sequence of a 16s rRNA gene that has at least 95% sequence identity to the polynucleotide sequence of SEQ ID NO;
3, as determined by a Smith-Waterman homology search algorithm using an affine gap search with a gap open penalty of 12, a gap extension penalty of 2, and a Blocks Substitution Matrix (BLOSUM) of 62.
6 Assignments
0 Petitions
Accused Products
Abstract
The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.
87 Citations
23 Claims
-
1. A pharmaceutical composition that reduces inflammation associated with Th17 differentiation in a subject in need thereof, that comprises a therapeutically effective amount of a single bacteria strain of the species Erysipelatoclostridium ramosum;
- and
a pharmaceutically acceptable excipient, diluent, or carrier; wherein the therapeutically effective amount comprises from about 1×
103 to about 1×
1011 CFU of the bacteria strain;wherein the bacterial strain is lyophilized; and wherein the bacteria strain comprises a polynucleotide sequence of a 16s rRNA gene that has at least 95% sequence identity to the polynucleotide sequence of SEQ ID NO;
3, as determined by a Smith-Waterman homology search algorithm using an affine gap search with a gap open penalty of 12, a gap extension penalty of 2, and a Blocks Substitution Matrix (BLOSUM) of 62.- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 19, 20, 21, 22, 23)
- and
-
11. A method of treating a condition in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition that comprises a bacteria strain of the species Erysipelatoclostridium ramosum and a pharmaceutically acceptable excipient, diluent, or carrier;
-
wherein the bacteria strain is present in an amount sufficient for treating a condition mediated by the Th17 pathway or by an increase in the IL-17 cytokine in the subject; wherein the therapeutically effective amount comprises from about 1×
103 to about 1×
1011 CFU of the bacteria strain;wherein the bacteria strain is lyophilized; and wherein the bacteria strain comprises a polynucleotide sequence of a 16s rRNA gene that has at least 95% identity to the polynucleotide sequence of SEQ ID NO;
3, as determined by a Smith-Waterman homology search algorithm using an affine gap search with a gap open penalty of 12, a gap extension penalty of 2, and a Blocks Substitution Matrix (BLOSUM) of 62. - View Dependent Claims (12, 13, 14, 15, 16, 17, 18)
-
Specification